Global respiratory drugs and devices market was valued at $55.4 billion in 2025 and is growing at a CAGR of 4.2% during the forecast period (2026-2035). Rising prevalence of chronic respiratory diseases, including asthma and COPD, increases the demand for long-term pharmacological treatments and supportive respiratory devices, driving market growth. As per the World Health Organization (WHO) Org., in June 2025,
Browse the full report description of “Respiratory Drugs and Devices Market Size, Share & Trends Analysis By Respiratory Drugs (Anticholinergics, Antihistamines, Beta2 Agonists, Antiasthmatic Combinations, Corticosteroids, Leukotriene Inhibitors, Mast Cell Stabilizers, Phosphodiesterase 4 (Pde4) Inhibitors, Bronchodilators, Decongestants, Expectorants, and Other Respiratory Drugs), By Product Type (Therapeutic Devices, Diagnostic And Monitoring Devices, and Consumables And Accessories), and By End User ( Hospitals, Home Care, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/respiratory-drugs-devices-market
- Burden of Disease
- 7 million people in the WHO European Region are living with chronic respiratory diseases (CRDs) such as asthma, COPD, and other lung conditions.
- 8 million new cases are diagnosed each year in the Region.
- CRDs are currently the sixth leading cause of death in the WHO European Region.
- Mortality & Disease Distribution
- COPD and asthma make up the majority of CRD cases in the Region.
- COPD accounts for 80 % of CRD-related deaths in the Region.
- COPD cases are projected to rise globally by 23 % from 2020 to 2050, with the steepest increases among women and in low- and middle-income countries (global projection).
- Economic Impact
- The annual economic cost of CRDs in the Region is estimated at $21 billion due to healthcare costs, lost productivity, etc.
- Productivity losses among people aged 30–74 due to CRDs are also estimated at over $20 billion.
Leading Companies Advancing the Respiratory Drugs and Devices Market
Major participants in the respiratory drugs and devices market, including AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Koninklijke Philips N.V., and Novartis AG, are contributing to ongoing advancements across the sector. These companies are focusing on the development of innovative respiratory therapies, inhalation devices, and integrated digital health technologies such as remote monitoring platforms, data-enabled treatment management, and analytics-driven care tools. Collectively, these efforts support improvements in disease management, treatment outcomes, and the overall efficiency of respiratory care delivery globally.
- In January 2026, EQT Life Sciences invested in Kinaset Therapeutics, a clinical-stage biopharma company, as part of an oversubscribed USD 103 million Series B round. This funding will support the development of frevecitinib, a novel inhaled dry powder treatment aimed at addressing asthma, particularly in patients inadequately controlled by existing therapies. Frevecitinib functions as an inhaled pan-JAK inhibitor, delivering concentrated medication directly to the lungs while reducing systemic exposure, thereby targeting the unmet need for effective inhaled anti-inflammatory therapies in the asthma population.
- In May 2025, Trixeo Aerosphere was approved in the UK as the first inhaled respiratory medicine using a next-generation propellant with near-zero Global Warming Potential (GWP), marking a significant advancement in treatments for chronic obstructive pulmonary disease (COPD). AstraZeneca's Trixeo features a propellant with 99.9% lower GWP compared to traditional pMDIs, delivering a fixed-dose triple-combination therapy with a carbon footprint akin to propellant-free inhalers. The approval by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) is supported by clinical data demonstrating bioequivalence and consistent safety profiles with existing medications. Ongoing regulatory reviews are in progress for Trixeo/Breztri in Europe, China, and other regions.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Respiratory Drugs
- By Product Type
- By End User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - AstraZeneca plc, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Koninklijke Philips N.V., Novartis AG, among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Respiratory Drugs and Devices Market Report Segment
By Respiratory Drugs
- Anticholinergics
- Antihistamines
- Beta2 Agonists
- Antiasthmatic Combinations
- Corticosteroids
- Leukotriene Inhibitors
- Mast Cell Stabilizers
- Phosphodiesterase 4 (Pde4) Inhibitors
- Bronchodilators
- Decongestants
- Expectorants
- Other Respiratory Drugs
By Product Type
- Therapeutic Devices
- Positive Airway Pressure Devices
- Masks
- Ventilators
- Nebulizers
- Humidifiers
- Oxygen Concentrators
- Inhalers
- Resuscitators
- Nitric Oxide Delivery Units
- Respiratory Oxygen Hoods
- Diagnostic And Monitoring Devices
- Respiratory Pulse Oximeters
- Respiratory Capnographs
- Respiratory Gas Analysers
- Respiratory Spirometers
- Respiratory Polysomnography (PSG) Devices
- Respiratory Peak Flow Meters
- Consumables And Accessories
- Disposable Masks
- Tracheostomy Tubes
- Nasal Cannulas & Other Consumables And Accessories
Global Respiratory Drugs and Devices Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/respiratory-drugs-devices-market